At AACR 2026, early clinical data surfaced across both targeted therapy and antibody-drug conjugate programs, including new activity signals for RAS-directed approaches and CLDN6-targeting ADCs. Investigators reported objective responses and strong disease control rates for zoldonrasib in KRAS G12D-mutant NSCLC cohorts previously treated with immune checkpoint inhibitors and platinum chemotherapy. In parallel, a first-in-human phase I study presented data on QLS5132, an ADC targeting CLDN6 in platinum-resistant ovarian cancer. The single-arm, dose-escalation trial reported partial responses in a subset of heavily pretreated patients, with adverse events dominated by predictable chemotherapy-type toxicities. Together, the AACR presentations highlight two tracks gaining traction: precision targeting in molecularly defined disease and ADC payload targeting for cancers with limited options after standard lines.